Compare monoclonal lab reagents for research






Suppliers for Lab Assays

TAT (HIV-1)

GWB-D5D417 GenWay Biotech 0.1 mg

HIV-1 gp41

E62H001 EnoGene 100ug

HIV-2 gp36

E62H003 EnoGene 100ug

HIV-1 gp41

GWB-424849 GenWay Biotech 1 ml

HIV-2 gp39

ant-153 ProSpec Tany 0.5mg
Description: Mouse Anti HIV-2 gp39

HIV-1 gp41

ant-159 ProSpec Tany 0.5mg
Description: Mouse Anti HIV-1 gp41

HIV-1 gp41

ant-160 ProSpec Tany ml
Description: Polyclonal Rabbit Anti HIV-1 gp41

Monoclonal GR monoclonal antibody

AMM00029G Leading Biology 0.05mg 633.6 EUR

Monoclonal TBP monoclonal antibody

APR13720G Leading Biology 0.1ml 633.6 EUR

Monoclonal Rsf1 monoclonal antibody

AMM07673G Leading Biology 0.05mg 633.6 EUR

Monoclonal Rsf1 monoclonal antibody

AMM07674G Leading Biology 0.1ml 633.6 EUR

Monoclonal EZH2 monoclonal antibody

AMM00030G Leading Biology 0.05mg 633.6 EUR

Monoclonal SirT1 monoclonal antibody

APR09951G Leading Biology 0.05mg 580.8 EUR

Monoclonal SirT1 monoclonal antibody

APR09952G Leading Biology 0.1ml 580.8 EUR

Monoclonal HDAC2 monoclonal antibody

AMM00031G Leading Biology 0.05mg 633.6 EUR

Our used TESTs in Pubmed.

Monoclonal VDR Antibody (monoclonal) (M02), Clone: 2F4

AMM04310G Leading Biology 0.1mg 580.8 EUR

Monoclonal WT1 Antibody (monoclonal) (M01), Clone: 2H4

AMM04323G Leading Biology 0.1mg 580.8 EUR

Monoclonal FASN Antibody (monoclonal) (M03), Clone: S1

AMM04516G Leading Biology 0.1mg 580.8 EUR

Monoclonal FH Antibody (monoclonal) (M07), Clone: 5C12

AMM04543G Leading Biology 0.1mg 580.8 EUR

Monoclonal G1P3 Antibody (monoclonal) (M02), Clone: M2

AMM04639G Leading Biology 0.1mg 580.8 EUR

Compare Pcr lab reagents for research




Suppliers for Lab ELISAs

ROX Reference Dye - 100 µM

PCR-356-10ML Jena Bioscience GmbH 10ml

ROX Reference Dye - 100 µM

PCR-356-1ML Jena Bioscience GmbH 1ml

T PCR SuperMix (-dye)

20-abx098005 Abbexa
  • 1 ml
  • 5 ml

T PCR SuperMix (+dye)

20-abx098006 Abbexa
  • 1 ml
  • 5 ml

Apex 6X Loading Dye

19-123 Genesee Scientific 1 Package/Unit
Description: 3 x 1.25ml, Type II Modified

Procion mx dye: 028 scarlet

40140058-1 Glycomatrix 10 g

Dye removal bag - EACH

DD4905007 Scientific Laboratory Supplies EACH

REC-1

ABC-TC0956 AcceGen 1 vial Ask for price

REC-2615 (HCl)

530142 MedKoo Biosciences 10.0mg 295 EUR

rec EGF (human)

H-7490.0100 Bachem 0.1mg 194.4 EUR

rec EGF (human)

H-7490.0500 Bachem 0.5mg 457.2 EUR

pGADT7- Rec- 53

PVT11254 Lifescience Market 2 ug 444 EUR

rec Leptin (human)

H-5578.0200 Bachem 0.2mg 194.4 EUR

rec Leptin (human)

H-5578.1000 Bachem 1.0mg 457.2 EUR

rec Leptin (mouse)

H-5582.0200 Bachem 0.2mg 194.4 EUR

Our used monoclonals in Pubmed.

Monoclonal CBS Antibody (monoclonal) (M01), Clone: 30

APG02460G Leading Biology 0.1mg 580.8 EUR

Monoclonal JUP Antibody (monoclonal) (M01), Clone: 2G9

APR16958G Leading Biology 0.1mg 580.8 EUR

Monoclonal MAK Antibody (monoclonal) (M01), Clone: 3E6

APR17272G Leading Biology 0.1mg 580.8 EUR

Monoclonal GCA Antibody (monoclonal) (M01), Clone: 2F5

APR16108G Leading Biology 0.1mg 580.8 EUR

Monoclonal ID2 Antibody (monoclonal) (M01), Clone: 3C3

APR16800G Leading Biology 0.1mg 580.8 EUR

Compare rec. lab reagents for research




Suppliers for Lab polyclonals

Dye 937

T18985-1mg TargetMol Chemicals 1mg
Description: Dye 937

Dye 937

T18985-50mg TargetMol Chemicals 50mg
Description: Dye 937

Dye 937

T18985-5mg TargetMol Chemicals 5mg
Description: Dye 937

Dye 993

T18986-10mg TargetMol Chemicals 10mg
Description: Dye 993

Dye 993

T18986-1g TargetMol Chemicals 1g
Description: Dye 993

Dye 993

T18986-1mg TargetMol Chemicals 1mg
Description: Dye 993

Dye 993

T18986-50mg TargetMol Chemicals 50mg
Description: Dye 993

REC-1

ABC-TC0956 AcceGen 1 vial Ask for price

REC-2615 (HCl)

530142 MedKoo Biosciences 10.0mg 295 EUR

rec EGF (human)

H-7490.0100 Bachem 0.1mg 194.4 EUR

rec EGF (human)

H-7490.0500 Bachem 0.5mg 457.2 EUR

pGADT7- Rec- 53

PVT11254 Lifescience Market 2 ug 444 EUR

rec Leptin (human)

H-5578.0200 Bachem 0.2mg 194.4 EUR

rec Leptin (human)

H-5578.1000 Bachem 1.0mg 457.2 EUR

rec Leptin (mouse)

H-5582.0200 Bachem 0.2mg 194.4 EUR

Our used References in Pubmed.

rec IL-3 (murine)

H-7370.0010 Bachem 10.0µg 457.2 EUR

rec PDGF BB (human)

H-7530.0002 Bachem 2.0µg 194.4 EUR

rec PDGF BB (human)

H-7530.0010 Bachem 10.0µg 457.2 EUR

rec PDGF AA (human)

H-7640.0002 Bachem 2.0µg 194.4 EUR

rec PDGF AA (human)

H-7640.0010 Bachem 10.0µg 457.2 EUR

Compare monoclonal lab reagents for research



Suppliers for Lab recombinants

BigLEN(rat)

TP2074-1mg TargetMol Chemicals 1mg
Description: BigLEN(rat)

BigLEN(rat)

TP2074-50mg TargetMol Chemicals 50mg
Description: BigLEN(rat)

BigLEN(rat)

TP2074-5mg TargetMol Chemicals 5mg
Description: BigLEN(rat)

Leptin rat

JP27295 Demeditec Diagnostics 96

Ghrelin (rat)

B5120-1 ApexBio 1 mg

Galanin, rat

5-01177 CHI Scientific 4 x 1mg

Ghrelin (Rat)

5-01201 CHI Scientific 4 x 1mg

Monoclonal GR monoclonal antibody

AMM00029G Leading Biology 0.05mg 633.6 EUR

Monoclonal TBP monoclonal antibody

APR13720G Leading Biology 0.1ml 633.6 EUR

Monoclonal Rsf1 monoclonal antibody

AMM07673G Leading Biology 0.05mg 633.6 EUR

Monoclonal Rsf1 monoclonal antibody

AMM07674G Leading Biology 0.1ml 633.6 EUR

Monoclonal EZH2 monoclonal antibody

AMM00030G Leading Biology 0.05mg 633.6 EUR

Monoclonal SirT1 monoclonal antibody

APR09951G Leading Biology 0.05mg 580.8 EUR

Monoclonal SirT1 monoclonal antibody

APR09952G Leading Biology 0.1ml 580.8 EUR

Monoclonal HDAC2 monoclonal antibody

AMM00031G Leading Biology 0.05mg 633.6 EUR

Our used antibodies in Pubmed.

Typhoid test card

INV-T810 Innovation Biotech 4.0mm (strip in a card) 25cards/box 0.5 EUR

MET Test Cassette

MET-1072 Innovation Biotech 4.0mm (strip in a card) 25cards/box 0.28 EUR

THC Test Cassette

THC-1092 Innovation Biotech 4.0mm (strip in a card) 25cards/box 0.27 EUR

Test Tube 16x100mm

3840/16X100 Scientific Laboratory Supplies PK100 66 EUR

Alcohol Test Strip

ALCOHOL-1211 Innovation Biotech 6.0mm (single pouch) 100pouches/box 0.44 EUR

recombinant Lab Reagents for Research





Promoted Lab polyclonals

Accu-Tell COVID-19 IgG/IgM Rapid Test

GEN-B352-20tests Accu test 20 tests 283.2 EUR

Accu-Tell COVID-19 IgG/IgM Rapid Test

GEN-B352-40tests Accu test 40 tests 385.2 EUR

2019-nCoV IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma)

GEN-402-25tests All test 25 tests 292.8 EUR

Human TES(Testin) ELISA Kit

EH1738 FN Test 96T 681.12 EUR

T(Testosterone) ELISA Kit

EU0400 FN Test 96T 571.5 EUR

Rat T(Testosterone) ELISA Kit

ER1462 FN Test 96T 628.92 EUR

Rat Cholesterol ELISA ELISA

E01A11128 BlueGene 96T 700 EUR

Goat Cholesterol ELISA ELISA

E01A46041 BlueGene 96T 700 EUR

Sheep Cholesterol ELISA ELISA

E01A98335 BlueGene 96T 700 EUR

Mouse Cholesterol ELISA ELISA

E01A19869 BlueGene 96T 700 EUR

Human Cholesterol ELISA ELISA

E01A2368 BlueGene 96T 700 EUR

Rabbit Cholesterol ELISA ELISA

E01A28609 BlueGene 96T 700 EUR

Bovine Cholesterol ELISA ELISA

E01A80905 BlueGene 96T 700 EUR

Our used rec. in Pubmed.

ARHGDIA Antibody / RHOGDI Antibody

F54788-0.08ML NSJ Bioreagents 0.08 ml 140.25 EUR

ARHGDIA Antibody / RHOGDI Antibody

F54788-0.4ML NSJ Bioreagents 0.4 ml 322.15 EUR

Tau (Ab-262) Antibody Antibody

E11-7239B EnoGene 100μg/100μl 225 EUR

Antibody Pair to APOA5 Antibody

E10-20042 EnoGene 100μg/100μl 225 EUR

CLCN5 Antibody / CIC-5 antibody

RQ6462 NSJ Bioreagents 100ug 356.15 EUR

Anti-Anti-SEPT5 Antibody antibody

STJ114819 St John's Laboratory 100 µl 332.4 EUR

Anti-Anti-SEPT2 Antibody antibody

STJ28365 St John's Laboratory 100 µl 332.4 EUR

Anti-Anti-SEPT7 Antibody antibody

STJ28963 St John's Laboratory 100 µl 332.4 EUR

Anti-Anti-SEPT3 Antibody antibody

STJ118990 St John's Laboratory 100 µl 332.4 EUR

Anti-Anti-SEPT1 antibody antibody

STJ119580 St John's Laboratory 100 µl 332.4 EUR

Downregulated RRS1 inhibits invasion and metastasis of BT549 through RPL11‑c‑Myc‑SNAIL axis

Regulator of ribosome synthesis 1 (RRS1) is a key factor in ribosome biosynthesis and other cellular functions. High level of RRS1 in breast cancer cell lines is associated with increased cell proliferation, invasion and migration. RRS1 controls the assembly of the 60s subunit and maturation of 25S rRNA during ribosome biosynthesis.
In this study, lentiviral transfection of sh‑RNA was used to knock down the level of RRS1, to detect the effect of RRS1 on cell function and to explore the specific mechanism of RRS1 affecting cell invasion and metastasis by COIP and dual‑luciferase reporter gene assays.
The present study found that RRS1 knockdown reduced the accumulation of ribosome protein L11 (RPL11) in the nucleolus, which then migrated to the nucleoplasm and bound to c‑Myc. This inhibited trans‑activation of SNAIL by c‑Myc and eventually decreased the invasion and metastasis capacity of the human breast cancer cell line BT549.
Taken together, RRS1 regulates invasion and metastasis of human breast cancer cells through the RPL11‑c‑Myc‑SNAIL axis. The findings are of great significance for exploring the mechanism of breast cancer invasion and metastasis and the corresponding regulatory factors.

Jumonji-C domain-containing protein 5 suppresses proliferation and aerobic glycolysis in pancreatic cancer cells in a cMyc-dependent manner

Despite the importance of metabolic reprogramming in cancer cells, the molecular mechanism regulating the tumor metabolic shift is still poorly understood. Deregulation of Jumonji-C domain-containing protein 5 (JMJD5) has been associated with multiple facets of biological processes in cancer cells.
However, the role of JMJD5 in pancreatic cancer cells has seldom been discussed and requires further investigation. In the present study, by silencing or overexpressing JMJD5 in pancreatic cancer cells, we examined the impact of JMJD5 on cell proliferation and glucose metabolism. Using a dual luciferase assay, we assessed the effect of JMJD5 on the transcriptional activity of the c-Myc target gene.
Analyzing The Cancer Genome Atlas and the Gene Expression Omnibus datasets revealed that low JMJD5 expression was associated with poor prognosis in patients with pancreatic cancer.
JMJD5 loss promoted pancreatic cancer cell proliferation and induced a cellular metabolic shift from oxidative phosphorylation to glycolysis. In addition, in vivo experiments confirmed that ectopic JMJD5 expression inhibited cancer cell growth and the expression of glycolytic enzymes, such as lactate dehydrogenase and phosphoglycerate kinase 1.
Moreover, JMJD5 negatively regulated c-Myc expression, the main regulator of cancer metabolism, leading to decreased c-Myc-targeted gene expression. Overall, the present study indicated that decreased JMJD5 expression promoted cell proliferation and glycolytic metabolism in pancreatic cancer cells in a c-Myc-dependent manner.

Imaging-Based Screening of Deubiquitinating Proteases Identifies Otubain-1 as a Stabilizer of cMYC

The ubiquitin-proteasome pathway precisely controls the turnover of transcription factors in the nucleus, playing an important role in maintaining appropriate quantities of these regulatory proteins. The transcription factor c-MYC is essential for normal development and is a critical cancer driver. Despite being highly expressed in several tissues and malignancies, the c-MYC protein is also continuously targeted by the ubiquitin-proteasome pathway, which can either facilitate or inhibit c-MYC degradation. Deubiquitinating proteases can remove ubiquitin chains from target proteins and rescue them from proteasomal digestion.
This study sought to determine novel elements of the ubiquitin-proteasome pathway that regulate c-MYC levels. We performed an overexpression screen with 41 human proteases to identify which deubiquitinases stabilize c-MYC. We discovered that the highly expressed Otubain-1 (OTUB1) protease increases c-MYC protein levels.
Confirming its role in enhancing c-MYC activity, we found that elevated OTUB1 correlates with inferior clinical outcomes in the c-MYC-dependent cancer multiple myeloma, and overexpression of OTUB1 accelerates the growth of myeloma cells. In summary, our study identifies OTUB1 as a novel amplifier of the proto-oncogene c-MYC.

Rational design of small-molecules to recognize G-quadruplexes of cMYC promoter and telomere and the evaluation of their in vivo antitumor activity against breast cancer

DNA G4-structures from human c-MYC promoter and telomere are considered as important drug targets; however, the developing of small-molecule-based fluorescent binding ligands that are highly selective in targeting these G4-structures over other types of nucleic acids is challenging.
We herein report a new approach of designing small molecules based on a non-selective thiazole orange scaffold to provide two-directional and multi-site interactions with flanking residues and loops of the G4-motif for better selectivity.
The ligands are designed to establish multi-site interactions in the G4-binding pocket. This structural feature may render the molecules higher selectivity toward c-MYC G4s than other structures.
The ligand-G4 interaction studied with 1H NMR may suggest a stacking interaction with the terminal G-tetrad. Moreover, the intracellular co-localization study with BG4 and cellular competition experiments with BRACO-19 may suggest that the binding targets of the ligands in cells are most probably G4-structures.
Furthermore, the ligands that either preferentially bind to c-MYC promoter or telomeric G4s are able to downregulate markedly the c-MYC and hTERT gene expression in MCF-7 cells, and induce senescence and DNA damage to cancer cells. The in vivo antitumor activity of the ligands in MCF-7 tumor-bearing mice is also demonstrated.

cMyc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation

SCLC is an aggressive malignancy with a very poor prognosis and limited effective therapeutic options. Despite the high tumor mutational burden, responses to immunotherapy are rare in SCLC patients, which may be due to the lack of immune surveillance.
Here, we aimed to examine the role and mechanism of oncogene MYC in the regulation of NKG2DL, the most relevant NK-activating ligand in SCLC-N.
Western Blotting, Immunofluorescence, flow cytometry, quantitative real-time PCR (qRT-PCR), Co-Immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), and Cytotoxicity assay were used on H2227 cells, H446 cells, and other SCLC cell lines, and we found that c-Myc negatively regulated NKG2DL expression in SCLC-N cells. Mechanistically, c-Myc recruited HDAC3 to deacetylate H3K9ac at the promoter regions of MICA and MICB, suppressing the MICA/B expression of SCLC-N cells and the cytotoxicity of NK cells.

c-Myc Epitope (Myc) Antibody

20-abx132269 Abbexa
  • 526.80 EUR
  • 159.60 EUR
  • 1513.20 EUR
  • 727.20 EUR
  • 410.40 EUR
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

c-Myc Epitope (Myc) Antibody

20-abx130438 Abbexa
  • 376.80 EUR
  • 910.80 EUR
  • 493.20 EUR
  • 184.80 EUR
  • 292.80 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

pMXs- c- Myc

PVT10447 Lifescience Market 2 ug 361.2 EUR

pCMV- Myc- C

PVT10696 Lifescience Market 2 ug 361.2 EUR

C- Myc Plasmid

PVT7185 Lifescience Market 2 ug 319.2 EUR

c Myc antibody

10R-8403 Fitzgerald 100 ul 471.6 EUR

OVA Conjugated c-Myc Epitope (Myc)

4-CPX162Ge21 Cloud-Clone
  • 237.19 EUR
  • 187.20 EUR
  • 559.49 EUR
  • 266.50 EUR
  • 412.99 EUR
  • 234.00 EUR
  • 1218.72 EUR
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg

OVA Conjugated C-Myc Epitope (Myc)

RPU50047-100ug Biomatik Corporation 100ug 475.2 EUR

OVA Conjugated C-Myc Epitope (Myc)

RPU50047-1mg Biomatik Corporation 1mg 1872 EUR

OVA Conjugated C-Myc Epitope (Myc)

RPU50047-50ug Biomatik Corporation 50ug 288 EUR

c-Myc(MYC275) Antibody

BNCA0275-250 Biotium 250uL 459.6 EUR

c-Myc(MYC699) Antibody

BNCA0699-250 Biotium 250uL 459.6 EUR

c-Myc(MYC909) Antibody

BNC800909-100 Biotium 100uL 238.8 EUR

c-Myc(MYC909) Antibody

BNC800909-500 Biotium 500uL 652.8 EUR

c-Myc(MYC275) Antibody

BNC800275-100 Biotium 100uL 238.8 EUR

c-Myc(MYC275) Antibody

BNC800275-500 Biotium 500uL 652.8 EUR

c-Myc(MYC699) Antibody

BNC800699-100 Biotium 100uL 238.8 EUR
Treatment with selective HDAC3 inhibitor up-regulated the expression of NKG2DL on SCLC-N cells and increased the cytotoxicity of NK cells. Furthermore, analysis of the CCLE and Kaplan-Meier plotter data performed the negative correlation between MYC and NKG2DL in SCLC-N cells and the correlation with the prognosis of lung cancer patients.
Collectively, the results provided the new insight into the role and mechanism of c-Myc/HDAC3 axis in NKG2DL expression and innate immune escape of SCLC-N, suggesting the potential target for SCLC-N immunotherapy.